Comparative Pharmacology
Head-to-head clinical analysis: PAXIPAM versus ZAXOPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAXIPAM versus ZAXOPAM.
PAXIPAM vs ZAXOPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
None Documented
None Documented
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Benzodiazepine
Benzodiazepine